NEW YORK (GenomeWeb) – Biological Dynamics announced today that has agreed to provide early access to its NanoVerita and ExoVerita lab-on-a-chip systems to researchers at the Knight Cancer Institute at Oregon Health & Science University (OHSU).
NanoVerita provides a sample-to-answer workflow for the isolation and fluorescent imaging of macromolecular targets such as cell-free DNA, while ExoVerita is designed to isolate and analyze extracellular vesicles to support assay development. Both use Biological Dynamics' AC electrokinetics, or ACE, technology for reversible macromolecule capture.
Under the terms of the deal, Biological Dynamics will provide early access to the NanoVerita and ExoVerita platforms to researchers at OHSU's Cancer Early Detection Advanced Research (CEDAR) Center. Additional terms were not disclosed.
"By collaborating with industry partners, we can access emerging technologies that can accelerate our research efforts," CEDAR Center Codirector Paul Spellman said in a statement. "We were impressed with the ability of Biological Dynamics' lab-on-chip platforms to quickly and simultaneously isolate DNA, RNA, and exosomal biomarkers, as well as scale as the project progresses to clinical validation. We will work with the team at Biological Dynamics to research new methods to detect and eliminate lethal cancers early."